IL6 and atherosclerosis: This inhibition prevents IL-6 from efficiently binding to the membrane-bound IL-6 receptor and initiating classic signaling.[44] As a result, sgp130 exerts a protective effect by impeding the inflammatory cascade involved in atherosclerosis, and thereby, sgp130Fc, a combination of sgp130 and IgG1-Fc, holds promise as a potential treatment for atherosclerosis.